Gerstein, H. C., Yang, M., Lee, S. F., Branch, K. R. H., Del Prato, S., Lam, C. S. P., … Sattar, N. (2024). Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial. Diabetes Obes Metab, 26(12), 6080–6084. https://doi.org/10.1111/dom.15957

Gerstein, Hertzel C., Mu Yang, Shun Fu Lee, Kelley R. H. Branch, Stefano Del Prato, Carolyn S. P. Lam, Renato D. Lopes, Richard Pratley, Julio Rosenstock, and Naveed Sattar. “Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.” Diabetes Obes Metab 26, no. 12 (December 2024): 6080–84. https://doi.org/10.1111/dom.15957.

Gerstein HC, Yang M, Lee SF, Branch KRH, Del Prato S, Lam CSP, et al. Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial. Diabetes Obes Metab. 2024 Dec;26(12):6080–4.

Gerstein, Hertzel C., et al. “Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.” Diabetes Obes Metab, vol. 26, no. 12, Dec. 2024, pp. 6080–84. Pubmed, doi:10.1111/dom.15957.

Gerstein HC, Yang M, Lee SF, Branch KRH, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N. Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial. Diabetes Obes Metab. 2024 Dec;26(12):6080–6084.